Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia |
| Type de publication | Journal Article |
| Year of Publication | 2017 |
| Auteurs | Cahu X, Carre M, Recher C, Pigneux A, Hunault-Berger M, Vey N, Chevallier P, Delaunay J, Gyan E, Lioure B, Bonmati C, Himberlin C, Hicheri Y, Guillerm G, Bouscary D, Larosa F, Ojeda-Uribe M, Bernard M, Bene MC, Ifrah N, Cahn J-Y |
| Journal | EUROPEAN JOURNAL OF HAEMATOLOGY |
| Volume | 98 |
| Pagination | 443-449 |
| Date Published | MAY |
| Type of Article | Article |
| ISSN | 0902-4441 |
| Mots-clés | acute myeloid leukemia, body-surface area, dose intensity, dose reduction |
| Résumé | ObjectivesAnthracyclines and cytarabine are cornerstones for intensive chemotherapy in acute myeloid leukemia (AML). The goals of this study were to comprehensively assess deviations from theoretical doses and the impact of body-surface area (BSA) on patients' characteristics, physicians' strategy, dose adjustment, and clinical outcome. MethodsThe GOELAMS 2001 phase III trial included 823AML patients below 60years of age. In the course of treatment, anthropomorphic parameters and chemotherapy doses were prospectively registered. ResultsVery high BSA (2.15m(2)) was the factor most significantly associated with the physician's decision to reduce chemotherapy doses during induction and postremission therapy. Despite similar AML characteristics and therapeutic strategies, the very high BSA group exhibited a significantly worse survival (5-years OS of 27%) compared to the low (BSA1.5m(2)), intermediate (1.5m(2) |
| DOI | 10.1111/ejh.12850 |